Overview

In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children (MEFI_III)

Status:
Completed
Trial end date:
2019-12-19
Target enrollment:
0
Participant gender:
All
Summary
This is a classical in vivo clinical trial, following World Health organization's recommendations, ran as a multisite study within Mozambique trying to assess the efficacy and safety in 4 sites of the two oral ACTS artemether-lumefantrine (AL) and Amodiaquine-Artesunate (AQ-AS), first line treatment for malaria in mozambique, for the treatment of uncomplicated malaria in children aged<5 years.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Centro de Investigacao em Saude de Manhica
Collaborator:
United States Agency for International Development (USAID)
Treatments:
Amodiaquine
Artemether
Artemether, Lumefantrine Drug Combination
Artesunate
Lumefantrine
Criteria
Inclusion Criteria:

- Ages 6 to 59 months

- Weight Greater than or equal to 5 kg

- Absence of severe malnutrition;

- Mono-infection with Plasmodium falciparum in blood, confirmed by microscopy;

- Parasite density between 2,000 and 200,000 asexual parasites per microliter of blood;

- Axillary temperature ≥ 37.5 C° or history of fever in the last 24 hours;

- Lack of danger signs, or no signs of severe and / or complicated malaria according to
the WHO definition

- Ability to swallow the drugs

- Haemoglobin greater than 5.0 g / dl

- Residents within the study area and have the possibility of an adequate follow-up in
the days of monitoring for a period of 28 days;

- Absence of a history of hypersensitivity to study medications;

- Informed consent of parents, guardians or caregivers (legal guardian) after explaining
the purpose of the study.

Exclusion Criteria:

- Presence of any danger sign or severe or complicated Plasmodium falciparum malaria
according to WHO definitions

- Presence of fever due to diseases other than malaria (eg measles, acute respiratory
infection, severe diarrhea with dehydration) or other known diseases, with chronic or
serious illnesses (cardiac, renal, hepatic or known infection with HIV AIDS),

- Presence of severe malnutrition (defined as a child whose growth pattern is below the
3rd percentile, mid-upper-arm circumference <110mm, weight / height <70% according to
the WHO tables, or the presence of bilateral edema of the lower limbs)

- Multi or mono-infection by another Plasmodium species detected by microscopy;

- Regular medication that may interfere with the pharmacokinetics of antimalarials;

- History of hypersensitivity or contraindication to study drug;

- A history of taking antimalarial drugs or drugs with antimalarial activity in less
than 7 days.

- Continuous prophylaxis with cotrimoxazole in HIV positive children